GeneDx Holdings annual r&d spending
2019
2020
2021
2022
2023
2024
2025
GeneDx Holdings R&D Spending Growth & History (WGS)
GeneDx Holdings's r&d spending was $72.0M for fiscal 2025.
View full GeneDx Holdings company overviewGeneDx Holdings annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $72.0M | $26.3M | +57.53% |
| 2024 | 2024-12-31 | $45.7M | −$12.5M | −21.53% |
| 2023 | 2023-12-31 | $58.3M | −$27.9M | −32.41% |
| 2022 | 2022-12-31 | $86.2M | −$19.0M | −18.03% |
| 2021 | 2021-12-31 | $105.2M | $32.5M | +44.65% |
| 2020 | 2020-12-31 | $72.7M | $37.8M | +108.25% |
| 2019 | 2019-12-31 | $34.9M | — | — |
GeneDx Holdings quarterly r&d spending
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $19.7M | $4.6M | +30.35% |
| Q1 2026 | 2026-03-31 | $19.8M | $7.2M | +57.46% |
| Q4 2025 | 2025-12-31 | $24.5M | $13.0M | +111.78% |
| Q3 2025 | 2025-09-30 | $19.8M | $8.2M | +69.99% |
| Q2 2025 | 2025-06-30 | $15.1M | $4.2M | +38.31% |
| Q1 2025 | 2025-03-31 | $12.6M | $1.0M | +8.73% |
| Q4 2024 | 2024-12-31 | $11.6M | −$660,000 | −5.39% |
| Q3 2024 | 2024-09-30 | $11.7M | −$2.6M | −18.36% |
| Q2 2024 | 2024-06-30 | $10.9M | −$6.2M | −36.39% |
| Q1 2024 | 2024-03-31 | $11.6M | −$3.0M | −20.73% |
| Q4 2023 | 2023-12-31 | $12.2M | −$12.1M | −49.73% |
| Q3 2023 | 2023-09-30 | $14.3M | $934,000 | +6.99% |
| Q2 2023 | 2023-06-30 | $17.1M | −$10.0M | −36.92% |
| Q1 2023 | 2023-03-31 | $14.6M | −$6.7M | −31.54% |
| Q4 2022 | 2022-12-31 | $24.4M | $2.1M | +9.53% |
| Q3 2022 | 2022-09-30 | $13.4M | −$4.5M | −25.11% |
| Q2 2022 | 2022-06-30 | $27.2M | $15.2M | +127.31% |
| Q1 2022 | 2022-03-31 | $21.3M | −$31.8M | −59.88% |
| Q4 2021 | 2021-12-31 | $22.2M | −$8.9M | −28.61% |
| Q3 2021 | 2021-09-30 | $17.8M | −$1.3M | −6.56% |
| Q2 2021 | 2021-06-30 | $12.0M | $2.6M | +27.68% |
| Q1 2021 | 2021-03-31 | $53.1M | $40.0M | +305.72% |
| Q4 2020 | 2020-12-31 | $31.2M | — | — |
| Q3 2020 | 2020-09-30 | $19.1M | — | — |
| Q2 2020 | 2020-06-30 | $9.4M | — | — |
| Q1 2020 | 2020-03-31 | $13.1M | — | — |
GeneDx Holdings r&d spending trends
Over the last five fiscal years, GeneDx Holdings's r&d spending decreased from $72.7M to $72.0M, a change of −$674,000. The latest reported quarter, Q2 2026, shows $19.7M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review GeneDx Holdings source filings ↗